Japan Price Revision: Mixture of Cuts And Increases Amid Supply Crisis
Market Expansion Rule Stays
Executive Summary
Japan’s annual drug reimbursement price revision for 2023 will cut approximately $2.3bn from national healthcare costs, and while several temporary price increases have been granted to cope with an ongoing supply crisis for some products, a system of one-off revisions for big sellers remains.
You may also be interested in...
Japan Readies One-Off Price Cuts For Big Sellers
Japanese regulatory authorities have announced a set of additional reimbursement price cuts for selected products in August, under which Novartis’s heart failure drug Entresto will see its price slashed by 15%. A batch of other newly approved drugs has also been priced.
What’s Next? Five Things To Look Out For In April
Generics Bulletin previews the biggest events and changes for industry in the coming month.
Japan’s Drug Distribution Crisis: Pharma Urges Govt To Reform Pricing System
The impact of drug shortages in Japan, including of essential products, is being considered as part of government-level discussions to consider the appropriateness of the current reimbursement pricing system. Amid rising production costs and wider global challenges, some experts in the industry are now asking for price increases.